close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

JNJ

238.75

-0.52%↓

UNH

274.86

-0.56%↓

TMO

538.28

-0.69%↓

ABT

110.13

-0.62%↓

ISRG

489.64

+0.49%↑

JNJ

238.75

-0.52%↓

UNH

274.86

-0.56%↓

TMO

538.28

-0.69%↓

ABT

110.13

-0.62%↓

ISRG

489.64

+0.49%↑

JNJ

238.75

-0.52%↓

UNH

274.86

-0.56%↓

TMO

538.28

-0.69%↓

ABT

110.13

-0.62%↓

ISRG

489.64

+0.49%↑

JNJ

238.75

-0.52%↓

UNH

274.86

-0.56%↓

TMO

538.28

-0.69%↓

ABT

110.13

-0.62%↓

ISRG

489.64

+0.49%↑

JNJ

238.75

-0.52%↓

UNH

274.86

-0.56%↓

TMO

538.28

-0.69%↓

ABT

110.13

-0.62%↓

ISRG

489.64

+0.49%↑

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Open

SectorGezondheidszorg

5.87 -5.48

Strong Buy

Prijsupdate 9 feb 2026, 15:43 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.88

Max

6.28

Belangrijke statistieken

By Trading Economics

Inkomsten

4.1M

-33M

Verkoop

6.1M

44M

EPS

-3.82

Winstmarge

-75.213

Werknemers

279

EBITDA

1.8M

-23M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+166.29% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

13M

116M

Vorige openingsprijs

11.35

Vorige sluitingsprijs

5.87

Nieuwssentiment

By Acuity

29%

71%

59 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 feb 2026, 23:57 UTC

Marktinformatie

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

DJ

Lezen

8 feb 2026, 23:47 UTC

Marktinformatie

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

DJ

Lezen

8 feb 2026, 23:43 UTC

Marktinformatie

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

DJ

Lezen

8 feb 2026, 23:34 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

8 feb 2026, 23:34 UTC

Marktinformatie

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

DJ

Lezen

8 feb 2026, 23:26 UTC

Marktinformatie

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

DJ

Lezen

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

DJ

Lezen

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

DJ

Lezen

8 feb 2026, 22:55 UTC

Winsten

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

DJ

Lezen

8 feb 2026, 22:55 UTC

Winsten

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

DJ

Lezen

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

DJ

Lezen

8 feb 2026, 22:55 UTC

Winsten

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

DJ

Lezen

8 feb 2026, 21:43 UTC

Marktinformatie

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

DJ

Lezen

8 feb 2026, 21:16 UTC

Marktinformatie

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

DJ

Lezen

8 feb 2026, 21:15 UTC

Marktinformatie

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

DJ

Lezen

7 feb 2026, 09:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

7 feb 2026, 09:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

7 feb 2026, 05:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

DJ

Lezen

7 feb 2026, 02:46 UTC

Acquisities, Fusies, Overnames

Big Money, High Anxiety -- Barrons.com

DJ

Lezen

6 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

6 feb 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

DJ

Lezen

6 feb 2026, 21:40 UTC

Acquisities, Fusies, Overnames

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

DJ

Lezen

6 feb 2026, 21:22 UTC

Marktinformatie

Mexico's Inflation Seen Accelerating in January -- Market Talk

DJ

Lezen

6 feb 2026, 21:17 UTC

Winsten

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

DJ

Lezen

6 feb 2026, 21:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

DJ

Lezen

6 feb 2026, 21:14 UTC

Acquisities, Fusies, Overnames

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

DJ

Lezen

6 feb 2026, 21:13 UTC

Winsten

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

DJ

Lezen

6 feb 2026, 21:13 UTC

Winsten

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

DJ

Lezen

6 feb 2026, 21:04 UTC

Marktinformatie

Gold Closes Out Volatile Week on Higher Note -- Market Talk

DJ

Lezen

6 feb 2026, 20:34 UTC

Winsten

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

166.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.67 USD  166.29%

Hoogste 23 USD

Laagste 12 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

59 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

JNJ

Johnson and Johnson

238.75

↓-0.52%

UNH

UnitedHealth Group Inc

274.86

↓-0.56%

TMO

Thermo Fisher Scientific Inc

538.28

↓-0.69%

ABT

Abbott Laboratories

110.13

↓-0.62%

ISRG

Intuitive Surgical Inc

489.64

↑ +0.49%
help-icon Live chat